Human medicines European public assessment report (EPAR): Kisqali, ribociclib, Breast Neoplasms, Date of authorisation: 22/08/2017, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Kisqali, ribociclib, Breast Neoplasms, Date of authorisation: 22/08/2017, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Kisqali, ribociclib, Breast Neoplasms, Date of authorisation: 22/08/2017, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Kisqali, ribociclib, Breast Neoplasms, Date of authorisation: 22/08/2017, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Kisqali, ribociclib, Breast Neoplasms, Date of authorisation: 22/08/2017, Revision: 11, Status: Authorised

Wil je het laatste nieuws in jouw mailbox ontvangen?
Meld je dan aan voor de nieuwsbrief.